Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma

Journal of Neuro-Oncology

Volumn 86, Issue 2, 2008, Pages 211-215

  Voloschin, Alfredo D ^a   Betensky, Rebecca ^b   Wen, Patrick Y ^c,d,e   Hochberg, Fred ^e,f   Batchelor, Tracy ^c,f  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

Primary CNS lymphoma; Radiographic response; Salvage therapy; Survival; Topotecan

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; PREDNISONE; RITUXIMAB; TEMOZOLOMIDE; TOPOTECAN; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RELAPSE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG MEGADOSE; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MALE; MEDICAL DECISION MAKING; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; RADIOSURGERY; SALVAGE THERAPY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DISEASE-FREE SURVIVAL; ENZYME INHIBITORS; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; SALVAGE THERAPY; TOPOTECAN; TREATMENT OUTCOME;

EID: 37249030398     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-007-9464-6     Document Type: Article

References (19)

1. CBTRUS, Central Brain Tumor Registry of the United States (2005-2006) Primary brain tumors in the United States. Statistical Report 1998-2002
2. Batchelor T, Carson K, O'Neill A et al (2003) Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: A report of NABTT 96-07. J Clin Oncol 21:1044-1049
3. Macdonald DR, Cascino TL et al (1990) Response criteria of phase II studies for supratentorial malignant glioma. J Clin Oncol 8(7):1277-1280
4. Nelson DF, Martz KL, Bonner H, Nelson JS, Newall J, Kerman HD, Thomson LW, Murray KJ (1992) Non-Hodgkin's lymphoma of the brain: Can high dose, large volume radiation therapy improve survival? Report on prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Onc Biol Phys 23:9-17
5. Abrey LE, Yahalom J, DeAngelis LM (1997) Relapse and late neurotoxicity in primary central nervous system lymphoma. Neurology 48:A18
6. Nguyen PL, Chakravarti A, Finkelstein DM, Hochberg FH, Batchelor TT, Loeffler JS (2005) Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. J Clin Oncol 23(7):1507-1513
7. Plotkin SR, Betensky RA, Hochberg FH, Grossman SA, Lesser GJ, Nabors LB, Chon B, Batchelor TT (2004) Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res 10(17):5643-5646
8. Herrlinger U, Brugger W, Bamberg M et al (2000) PCV salvage therapy for recurrent primary CNS lymphoma. Neurology 54:1707-1708
9. Reni M, Mason W, Zaja F et al (2004) Salvage chemotherapy with temozolomide in primary CNS lymphomas: Preliminary results of a phase II trial. Eur J Cancer 40:1682-1688
10. Enting RH, Demopoulos A, DeAngelis LM, Abrey LE (2004) Salvage therapy for primary CNS lymphoma with a combination of temozolomide and rituximab. Neurology 63:901-903
11. Fischer L et al (2006) Prospective trial on topotecan salvage therapy in primary CNS lymphoma. Ann Oncol 17:1141-1145
12. Soussain C, Hoang-Xuan K, Levy V (2004) Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. Bull Cancer 91(2):189-192
13. Tyson RM, Siegal T, Doolittle ND, Lacy C, Kraemer DF, Neutwelt EA (2003) Current status and future of relapsed primary central nervous system lymphoma (PCNSL). Leuk Lymphoma 44(4):627-633
14. Bashir R, Freedman A, Harris N, Bain K, Nadler L, Hochberg F (1989) Immunophenotypic profile of CNS lymphoma: A review of eighteen cases. J Neurooncol 7(3):249-254
15. Raizer JJ, DeAngelis L, Zelenetz A, Abrey L (2000) Activity of rituximab in primary central nervous system lymphoma. Proc Am Soc Clin Oncol 19:166a
16. Sung C, Blaney SM, Cole DE et al (1994) A pharmacokinetic model of topotecan clearance from plasma and cerebrospinal fluid. Cancer Res 54:5118-5122
17. Preti HA, Plunkett W, Sarris AH, Younes A, Hagemeister F, Rodriguez MA, Romaguera J, McLaughlin P, Bachier C, Cabanillas F (1995) Preliminary results of a phase II trial of topotecan in patients with relapsing lymphoma. Blood 86(10, Suppl 1):820A
18. Wong ET, Berkenblit A (2004) The role of topotecan in the treatment of brain metastases. Oncologist 9(1):68-79
19. Voloschin A, Wen P, Hochberg F, Batchelor T (2004) Topotecan as salvage therapy for refractory or relapsed primary central nervous system lymphoma: Final report. Neurology 62:A478